Active Biotech appoints CSO
This article was originally published in Scrip
The Swedish biotech firm Active Biotech has appointed Dr Helén Tuvesson as its new chief scientific officer, effective 1 April. Dr Tuvesson has been with the company since 1998, working in preclinical development, R&D management and most recently within the senior management team. She will report to president and CEO Tomas Leanderson.
You may also be interested in...
The Indian pharmaceutical sector is recognised for its entrepreneurial spirit. Many companies have crafted successful business strategies by offering API manufacturing, drug discovery, CRAMS and other services to global pharmaceutical customers. Others market their products overseas while leveraging growth opportunities on their home turf. The following five domestic companies are well worth watching in 2011.
Affimed Therapeutics (Germany) has appointed Dr Adi Hoess as its new chief commercial officer. Effective immediately, Mr Hoess will focus on commercial and strategic management and business development, complimenting his previous senior management and business development roles at Jenowis, Carl Zeiss Jena, MorphoSys and Jerini. His appointment also coincides with the continued development of the company's lead product candidate, AFM13, for Hodgkin's lymphoma, which entered a Phase I clinical trial last November (scripintelligence.com, 15 November 2010).
French biotech company TxCell, which develops cell-based therapies for severe chronic inflammatory diseases, has appointed Dr François Meyer as chief executive officer. Dr Meyer has held senior positions at Ciba-Geigy Pharma, Sandoz Pharma, Gencell and Aventis Pharma, and until 2006 served as CEO of Centelion. Dr Meyer joins as TxCell – a spin-off of the French National Institute for Health and Medical Research (Inserm) – prepares to move two product candidates through clinical trials: Phase IIb trials for refractory Crohn's disease and Phase I/II trials for refractory rheumatoid arthritis respectively.